\
&
Contact us
\
&
Contact us
This was 7 months ago
LocationOnline
ProgrammesThe Language Technology Landscape Conference disseminates the findings from the Market Study conducted by Nimdzi Insights.
Nimdzi Insights and its partners are conducting a comprehensive Market Study on Language Technologies for the European Commission to assess the development, quality, and global impact of language technologies globally and in Europe. The Language Technology Landscape Conference will present the results of a two-year study, highlighting trends in the language technology market with a focus on foundational, text-based, and speech-based language technologies. This half-day online event will be hosted on WebEx, with keynote speakers from the European Commission and Nimdzi Insights, as well as guest appearances from the buyer and technology provider sides.
For more information and to register for the event, please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
